OverviewSuggest Edit

BenevolentAI harnesses artificial intelligence to enhance and accelerate scientific discovery by making sense of highly fragmented information to create new insights and usable knowledge that benefit society. The Company's mission is to bring the power of humans and machines together to make sense of and drive rapid scientific discovery. It's proprietary AI technology, the Judgement Augmented Cognition System uses cutting edge deep learning techniques to change the way knowledge is created, connected and applied, and enables the mass analysis of vast amounts of scientific information.
HQLondon, GB
Employee Ratings4.3

Latest Updates

Employees (est.) (Oct 2019)190(+4%)
Job Openings26

Key People/Management at BenevolentAI

Kenneth Mulvany

Kenneth Mulvany

Joanna Shields

Joanna Shields

Group CEO
Michael Brennan

Michael Brennan

Head of Corporate Development
Jackie Hunter PhD CBE FBPharmacolS FMedSc

Jackie Hunter PhD CBE FBPharmacolS FMedSc

Bart Swanson

Bart Swanson

Non-Executive Director
Jerome Pesenti

Jerome Pesenti

Non-Executive Director
Show more

BenevolentAI Office Locations

BenevolentAI has offices in London, Cambridge, Brooklyn and Antwerpen
London, GB (HQ)
4-8 Maple St, Bloomsbury
Cambridge, GB
Minerva Building, Babraham Hall, Babraham
Antwerpen, BE
Franklin Rooseveltplaats 12
Brooklyn, US
81 Prospect St
Show all (4)

BenevolentAI Financials and Metrics

Summary Metrics

Founding Date


BenevolentAI total Funding

$305 m

BenevolentAI latest funding size

$90 m

Time since last funding

a month ago

BenevolentAI investors

BenevolentAI's latest funding round in September 2019 was reported to be $90 m. In total, BenevolentAI has raised $305 m. BenevolentAI's latest valuation is reported to be $1 b.
View all funding rounds

BenevolentAI Revenue

Market valuation

Show all financial metrics

BenevolentAI Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size

BenevolentAI Online and Social Media Presence

Embed Graph

BenevolentAI News and Updates

Baroness Joanna Shield's BenevolentAI Is Reportedly Preparing To Slash Its $2 Billion Valuation

The company, led by Baroness Joanna Shields, the former European boss of Facebook, is reportedly raising another round of funding at a valuation "far below" its $2 billion valuation.

BenevolentAI starts AI collaboration with AstraZeneca to accelerate drug discovery

BenevolentAI, is an AI company where AI actually means something. Founded in 2013, it focuses on ‘accelerating the journey from data to medicines.’ To achieve that, it’s raised a whopping $202 million to look at early drug discovery to late-stage clinical development and has a research facility in C…

Algorithms vs Alzheimers? BenevolentAI Hits $2B High

Some 76 startups now using AI in drug discovery - with traditional discovery then route to market typically taking over a decade The post Algorithms vs Alzheimers? BenevolentAI Hits $2B High appeared first on Computer Business Review.

Woodford-backed BenevolentAI raises $115m as founder allays robot fears

The founder of artificial intelligence (AI) startup BenevolentAI believes robots will be able to exist in a symbiotic relationship with humans, refuting the idea that they will replace all jobs. Speaking to City A.M., Ken Mulvany said AI will "multiply the power of our intellect" in the same way …

UPDATE 1-AI drug hunter BenevolentAI worth $2 bln after fund raising

LONDON, April 19 (Reuters) - BenevolentAI, a British drug developer that uses artificial intelligence to identify new medicine candidates, said it had raised $115 million in a funding round that valued it at $2 billion.

UK drug discovery startup BenevolentAI raises $115M

U.K.-based artificial intelligence company BenevolentAI Ltd. today announced the completion of a $115 million funding round that values the London startup at a cool $2 billion. The round, said to be one of the largest ever in the AI pharmaceutical sector, was led by BevenolentAI’s existing backers i…
Show more

BenevolentAI Blogs

Biomedical relation extraction

In a recent paper, we proposed a new relation extraction model built on top of BERT. Given any paragraph of text (for example, the abstract of a biomedical journal article), our model will extract all gene-disease pairs which exhibit a pre-specified relation.

Mind the gap: the diversity issue in medical research.

There is a data diversity problem in medical research; spanning from identifying which topic to study, to selecting patients for clinical trials. It is critical that researchers collaborate and engage in collective action to ensure that every patient can benefit from our innovations and discover…

BenevolentAI announces $90 million investment from Temasek

BenevolentAI has raised $90 million from Temasek, a Singapore-headquartered investment company. The funding will be used to scale and further develop the Benevolent Platform for drug discovery and development as well as further progress BenevolentAI drug programmes developed in-house and through…

Advancing Oncology Drug Development with Precision Medicine

Our recent collaboration with Novartis in oncology will help gain a better understanding of patient and disease heterogeneity by combining expertise in precision medicine and machine learning to accelerate the process of delivering the next-generation cancer therapies to the clinic.

BenevolentAI announces Agreement with leading healthcare company to leverage BenevolentAI’s technology platform

BenevolentAI have collaborated with Novartis Global Drug Development on an initial project in oncology, which will see the application of our AI and machine learning technology to stratify patients and gain a better understanding of patient and disease heterogeneity to more precisely target medi…

Interpret - Constructing large scale biomedical knowledge bases from scratch with rapid annotation of interpretable patterns

We have developed machine learning methods to improve the way scientists make sense of huge amounts of data and discover non-obvious relationships between genes, diseases and molecules, based on existing relationships.
Show more

BenevolentAI Frequently Asked Questions

  • When was BenevolentAI founded?

    BenevolentAI was founded in 2013.

  • Who are BenevolentAI key executives?

    BenevolentAI's key executives are Kenneth Mulvany, Joanna Shields and Michael Brennan.

  • How many employees does BenevolentAI have?

    BenevolentAI has 190 employees.

  • Who are BenevolentAI competitors?

    Competitors of BenevolentAI include Lantern Pharma, CloudMedx and Human Longevity.

  • Where is BenevolentAI headquarters?

    BenevolentAI headquarters is located at 4-8 Maple St, Bloomsbury, London.

  • Where are BenevolentAI offices?

    BenevolentAI has offices in London, Cambridge, Brooklyn and Antwerpen.

  • How many offices does BenevolentAI have?

    BenevolentAI has 4 offices.